Chlorogenic Acid Inhibits Lipid Deposition by Regulating the Enterohepatic FXR‐FGF15 Pathway

作者：Xiaolin Ye, Jing Li, Zhe Gao, Dongwei Wang, Hongyu Wang, Jie Wu · 发表于：BioMed Research International · 年份：2022 · DOI：10.1155/2022/4919153 · 被引用次数：25 · 研究领域：Fibroblast Growth Factor Research、Parathyroid Disorders and Treatments、Kruppel-like factors research

Aim . Chlorogenic acid (CGA) is a natural polyphenolic compound found in human dietary products. Previous studies have confirmed that CGA has many biological activities, such as regulating glucose and lipid metabolism and improving insulin resistance. However, its underlying mechanisms of action remains unclear. Here, we demonstrate the protective effects and molecular mechanisms of action of CGA in reducing weight gain and hyperlipidemia in mice fed with a high‐fat diet (HFD). Methods and Results . C57BL/6 mice were fed with normal chow or HFD; half of the mice in each group received CGA treatment by oral gavage for 16 weeks. CGA treatment was found to significantly inhibit HFD‐induced weight gain and hyperlipidemia and increased energy expenditure by promoting the expression of genes involved in thermogenesis and mitochondrial biogenesis. Furthermore, CGA was shown to inhibit the enterohepatic farnesoid X receptor (FXR) fibroblast growth factor 15 (FGF15) pathway and changes serum bile acid (BA) pool, thereby contributing to the increased expression of cholesterol 7 α ‐hydroxylase (CYP7A1). Conclusions . CGA increases the metabolic elimination of cholesterol by inhibiting the enterohepatic FXR/FGF15 pathway.